Hyperfine

HYPR · NASDAQ

$0.774−$0.0032 (−0.41%)TodayMarket closed · Oct 20, 7:45 PM ET

Prev close $0.7772

HYPR analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $2.07 (+168.0% upside)

Low: $1.62
Now: $0.774
High: $2.63

Upgrades and downgrades

The latest rating actions, newest first

HYPR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BTIG	Sep 22, 2026	Maintains	Buy	$2.00	56%
BTIG	Sep 14, 2026	Maintains	Buy	$2.00	56%
B. Riley Securities	Aug 10, 2026	Maintains	Buy	$2.00 → $1.60	37%
BTIG	Apr 29, 2026	Initiates	Buy	$2.00	56%
Lake Street	Mar 19, 2026	Maintains	Buy	$2.00 → $2.50	36%

The case for and against

Updated Oct 21, 2026

Bull case

Hyperfine is well-positioned for durable growth because its Swoop platform is gaining traction across hospitals, neurology offices, and international markets, with more than 200 systems deployed worldwide and 12 units sold in 2Q26, up from 8 a year earlier. Its appeal is strengthened by a compelling 1- to 1.5-year hospital ROI, rising utilization, minimal pricing resistance, and expanding clinical utility from next-generation Model 2 hardware and recurring FDA-cleared Optive AI software updates. Financially, the company has posted gross margins above 50% for four consecutive quarters, reported $3.9M of 2Q26 revenue and $43.5M in cash, and is targeting $20M-$22M of revenue in FY26 with cash burn declining toward $26M-$28M.

Bear case

Hyperfine is facing a fragile commercial setup because its Model 2 ramp is still early, its install base remains relatively small, and quarterly results can be lumpy if adoption or install timing slips. The business also carries multiple execution risks that could pressure fundamentals, including future capital needs, regulatory clearances, reimbursement updates, supplier pricing pressure from a limited vendor base with a single-source magnet supplier, and competitive pressure from larger MRI players. Although the guidance midpoint implies only a ~10% y/y reduction in cash burn and the company is targeting a large >$16B U.S. market, weak operating leverage, financing dependence, and international/geopolitical risk keep the outlook negative.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.